Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
about
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesThe role of maintenance therapy in multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyHow we manage autologous stem cell transplantation for patients with multiple myelomaPhase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.New approaches to management of multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.The role of tandem stem cell transplantation for multiple myeloma patients.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Management of Elderly Patients with Plasma Cell Myeloma.Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future.Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?Age and aging in blood disorders: multiple myeloma.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.Improved survival of older patients with multiple myeloma in the era of novel agents.Hypoxia-regulated gene network in drug resistance and cancer progression.
P2860
Q27026478-A599AF0D-EB21-48C9-8156-E6FA4C410D2BQ28071644-72E5CA67-A980-4F86-B582-4071C2F9C7B8Q28082910-5849BF9B-C90B-4513-BE10-64ADFA1720B7Q34019581-E6C639D4-DDDB-4A65-903E-548DD09713FBQ34990174-4E563A45-598C-4D56-A425-F2EEACE6864CQ35410550-94397F75-C06D-403E-B138-7255EBD03997Q36839385-9E3853C3-40C2-4DEB-9A20-137E55F977E1Q38191867-F6B63A23-0E25-4647-B559-7362CA3C0BEBQ38375463-6BDA13B8-066D-4276-9030-0EFA0AB18F8EQ38385465-12435834-B48A-4CA7-9D19-69CB76AE94C1Q38554884-356BCC9E-665B-48B9-A21B-6E7ABDCDE3EFQ38677358-64F56D24-A3AA-4480-8E18-797BDDBC05D0Q38738098-D06929E0-FD85-40A9-A23F-C5E8FE3979ABQ38815405-CAD6046B-CFD2-48F2-AF37-AF88209A936BQ39001325-E0AC7BDF-383D-4954-AC5C-4BBEC953DFFEQ39295929-48026BF2-8EE8-4029-89DA-296EEAAAE282Q40389797-071EA4E1-E5D3-4514-8256-6BECEA2B2FF9Q40469944-B4757690-B19D-4D42-B028-4365A1DF418BQ40763491-C6430812-AC01-404B-9D68-C5B17AE3D840Q42005212-10BBCFC7-EAF0-46BC-BD79-B7C0146933B2Q42009130-3BB7722E-61FF-4CCB-8E80-2929C6DD205BQ42362041-22D877C5-4EA4-43BE-876D-D9872C2EA942Q42716199-DA4FF4A2-25D1-42E1-B805-8CABB3DB1EA4Q47418005-C40317D0-8415-4116-870F-EF83F26FFD38Q47794767-B889FDCD-3BAB-4D88-AC80-92E94EEFF5E4Q48188365-9E6B99C6-1A9B-4AE9-A57A-4A200ACA1289Q48197735-A4CFAFE4-C25F-4DC4-87E1-8DDAB98617B4Q54354000-1B19C7BB-2FF9-4D72-8D42-04A128397785
P2860
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Bortezomib induction, reduced- ...... for myeloma: updated results.
@en
Bortezomib induction, reduced- ...... for myeloma: updated results.
@nl
type
label
Bortezomib induction, reduced- ...... for myeloma: updated results.
@en
Bortezomib induction, reduced- ...... for myeloma: updated results.
@nl
prefLabel
Bortezomib induction, reduced- ...... for myeloma: updated results.
@en
Bortezomib induction, reduced- ...... for myeloma: updated results.
@nl
P2093
P50
P1433
P1476
Bortezomib induction, reduced- ...... e for myeloma: updated results
@en
P2093
Anna Marina Liberati
Claudia Crippa
Francesca Patriarca
Giuseppe Pietrantuono
Maria Teresa Petrucci
Mario Boccadoro
Norbert Pescosta
Paola Omedé
Samantha Ferrari
Sara Pezzatti
P304
P356
10.1182/BLOOD-2013-02-483073
P407
P50
P577
2013-06-17T00:00:00Z